Lupin Ltd Q3 FY2023 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/kkwz4pu0khiddy5l9zwqraz1.pdf

Key Takeaways


US Generics: The Turnaround Thesis

Ramesh Swaminathan: "You recognize, Sameer, as well as I do, it was a feast for quite some time. There has been a bit of a famine out there in the last two to three years. But it's not as though this party will never begin again. It will -- so once we get the products in place, things should be much better."

Spiriva & The Pipeline Catalyst Stack

Vinita Gupta: "It's April without inspection and July with inspection. So, the FDA decides that they want to come and inspect, then it will -- the TAD date will be July. But if they decide that they don't want to inspect, which is very hard for us to predict, the agency is going to inspect or not, then it's going to likely be April."

India: Investing Through a Soft Patch

Nilesh Gupta: "My expectation is that, from the second quarter, we will be growing overall at a rate faster than the market."

Margins: The Long Climb Back

Ramesh Swaminathan: "Clearly, it's an absolute nadir from my perspective and 18% to 20% over the next two to three years is -- from my perspective is a certainty."

Compliance & Manufacturing Footprint

Nilesh Gupta: "From the industry perspective, I think there is an over-heightened sensitivity to every 483 that there is. But obviously if there are excessive number of 483s or obviously other regulatory action, that is of concern."

Guidance & Commitments

CommitmentSpecificsTimeline
Spiriva approvalTarget action date April (without inspection) or July (with inspection); approval expected with "great deal of confidence"H1 CY2023
Darunavir launch600 mg and 800 mg strengthsQ1 FY24
Pegfilgrastim approvalAll agency questions believed satisfiedNext couple of months
India growthGrow overall at a rate faster than the marketFrom Q2 FY24
Q4 FY23 EBITDA marginIn the same range as Q3Q4 FY23
US generics EBITDARise above company average level, subject to Spiriva and Darunavir launchesFY24
EBITDA margin targetReach 17–18%; 18–20% described as "a certainty"Next 2–3 years
R&D expense ratioDecline 1–2 percentage points as a percent of salesOver time
Cost savings programFull INR600 crores benefit to flow into P&LWhen complete (no date)
Injectables launchesFour to five products (Glucagon, Bumetanide, Famotidine, plus in-sourced products)FY24

Key Metrics

MetricQ3 FY23
Revenue₹4,244 cr, up 3.7% QoQ and 3.8% YoY
Gross margin59.8%, up from 58.1% in Q2 FY23; improved US mix and lower freight
Operating EBITDA margin (excl. FX and other income)12.2%, up 160 bps QoQ on higher sales, gross margins and cost control
US business revenue growth (local currency)11.2% QoQ, driven by new launches and acquired brands; down 12.3% YoY
US quarterly revenue run rate$170 mn plus with current products, before additional new launches
India branded formulations growth7.5% in Q3 vs market growth of 10%; grew 2.6% YoY
India sales force7,100 reps (9,300 total sales force) after adding ~1,000 reps and creating six new divisions
New product launch contribution (US)$20 mn in Q3 revenue from 8 NPLs year-to-date
API business growth12.7% QoQ, 9.8% YoY, led by cephalosporins recovery
EMEA revenue growth11.1% YoY, driven by Luforbec in UK and NaMuscula in Germany
Growth Markets revenue growth23.5% YoY; declined 5.9% QoQ
Employee benefit cost₹764 cr, marginally down from ₹771 cr in Q2 FY23; ongoing range expected at 18.5%–19% of sales
Net debt₹3,400 cr; gross debt at ₹4,600 cr, reflecting brand acquisitions and capex
R&D expense~8% of sales for FY23, expected to decline by 1–2 ppt over time